List of Artificial Intelligence Companies in Massachusetts - 146

908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company’s devices are used at the point of need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in bioprocessing, pharma/biopharma, forensics, life sciences research and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, microfluidic sampling and separations, software automation, and machine learning.

Abiologics is pioneering a new class of supranatural and programmable biologics, called Synteins™. The Abiologics platform leverages cutting-edge generative artificial intelligence and high-throughput chemical protein synthesis to create Synteins with powerful, desirable pharmacological properties, redefining what therapeutics can achieve for patients across a range of disease areas. Abiologics was founded by Flagship Pioneering in 2021.

At Activ Surgical, our mission is for every surgical imaging system to deliver intelligent information that reduces surgical complication rates, ushering in a new standard of patient care and safety. Having completed the world’s first autonomous robotic surgery of soft tissue in 2018, the company is focused on enhanced, real-time visualization capabilities for surgeons that combine advanced augmented reality (AR), artificial intelligence (AI), and machine learning (ML) technology. Our vision is to transform the collective surgical experience by leveraging emerging technologies and data into insights that make world-class surgery accessible for all.

Admetsys is a biomedical technology company specializing in critical care automation. The company's flagship PrecisionOne system is the first fully automated glycemic control system and continuous blood diagnostics platform for hospital care. The company was founded to commercialize the next generation of medical automation technology: continuous real-time biosensing, robotics, artificial intelligence and learning algorithms, intelligent therapeutic delivery, and advanced data telemetry.

Affinia Therapeutics is an innovative gene therapy company focused on broadening the reach of gene therapy. Our proprietary Affinia Rationally-designed Therapies (ART) platform is created to address key limitations of conventional gene therapies, by developing novel capsids, novel promoters, and novel manufacturing approaches to developing gene therapies for rare and prevalent devastating diseases. We are backed by a strong syndicate of life science investors and have ambitious plans to have a dramatic impact on the lives of patients around the world.

Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that have the potential for oral delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND enabling studies.

Our mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. By continuing to deepen our understanding of rare disease, which began with our pioneering work in complement biology, we are able to innovate and evolve into new areas where there is great unmet need and opportunity to help patients and families fully live their best lives. Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work. We invest in and value people who believe in the importance of our purpose and understand what it takes to deliver on it. Alexion has over 3,000 talented colleagues dedicated to serving people living with rare diseases in more than 50 countries around the world. Our global headquarters are based in Boston, Massachusetts and our EMEA headquarters are in Zürich, Switzerland. We also have a Research Center of Excellence in New Haven, Connecticut, global supply chain and operations headquarters in Ireland, as well as local and regional operations in countries around the world. At Alexion, our passion drives us to continuously innovate and create meaningful value in all we do. In doing so, we change lives for the better – ours, people living with rare diseases, and the communities we serve. Every day.

Alltrna is the first transfer RNA (tRNA) platform company, and our mission is to unlock tRNA biology and pioneer tRNA therapeutics to regulate the protein universe and resolve disease. Founded at Flagship Labs in 2018, Alltrna has mapped tRNA biology to systematically design tRNA medicines and encode a completely new, unifying approach to treating both rare and common human diseases driven by shared genetic mutations. Alltrna’s platform combines internal expertise and proprietary machine learning tools to unlock the entire tRNA biology space. We have an unprecedented opportunity to advance a single tRNA medicine to restore disrupted protein production, regardless of target, for thousands of diseases with the same underlying genetic mutation.

Allurion was founded in 2009 with one mission: end obesity. The Allurion Program combines medical, digital, and nutritional approaches and engages an entire team to jumpstart weight loss and form lifelong healthy habits. Allurion has already helped thousands of people around the world lose weight, develop lifelong healthy habits, and transform their lives, with over 100,000 balloons placed, and over 1,000,000kg lost worldwide.

Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.

Anumana™ is harnessing industry-leading AI and translational science to decode electrical signals from the heart as never before, empowering healthcare providers to transform patient care throughout the cardiac clinical pathway. Serious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate. Unfortunately, these conditions can remain undiagnosed until the patient suffers a life-threatening event. Innovations enabling earlier diagnoses could address this unmet medical need and empower healthcare providers to intervene with life-saving treatments. Anumana recently acquired NeuTrace and is leveraging the power of novel ECG-EGM-EMR integration for clinically valuable, actionable insights. With nference's proprietary nSights real-world evidence generation platform, built on data from leading health systems, we combine unparalleled longitudinal structured and unstructured electronic medical record data with diagnostic and interventional ECGs and EGMs. By applying AI techniques to these electrical signals from the heart, the company has uncovered clinically critical electrical signatures and patterns unrecognizable to the human eye. The resulting software products can be integrated into routine clinical practice for earlier disease diagnosis and in-procedure decision-making. Anumana's 75+ peer-reviewed publications and ongoing research show significant promise to detect and diagnose otherwise hidden conditions earlier and uncover actionable insights for valuable patient interventions. The opportunity to offer clinical decision support tools for each unique patient throughout the cardiac care continuum paves the way for precision medicine. Anumana strives to introduce a new standard of care in cardiac clinical care supported by reimbursement.

Apriori is working to create a world where humanity is protected against viral threats. Our pioneering approach centers on a unique technology platform, which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants. Apriori was founded in 2020 in Flagship Labs, a unit of Flagship Pioneering.

Arbor Bio is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines, with the most extensive toolbox of proprietary genomic editors in the industry. We have the unique ability to work backward from disease pathology and choose the optimal editors or combination of editors for the disease in question.

Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.

Arrow Dx is combining Nanotechnology and Artificial Intelligence (AI) to create an inexpensive, sensitive test to screen early for non-alcoholic fatty liver disease (NAFLD). Our aim is to provide physicians with an alternative to liver biopsy which detects the disease too late. We are working to solve the lack of rapid, reliable, point-of-care, and inexpensive diagnostic devices by bring faster, inexpensive and mobile testing for many other applications that require a rapid response (e.g., epidemic/pandemics, public health crisis, early diagnosis for rising complex non-communicable diseases, testing in emergency rooms). Our technology makes it more affordable for smaller healthcare providers such as Physician Office Labs (~100,000 in the U.S.), independent physicians and public health workers to access diagnostics due to our significantly lower cost as well as our portable, small compact size. Finally, we are also working to create a test for COVID-19 as well as other viruses, initially quantifying the virus in wastewater to help public health authorities and later to detect it in biological samples from individuals and patients.

Arxspan provides cloud-based solutions to meet the scientific data management needs of leading life sciences, chemicals, and scientific companies globally. Arxspan offers ArxLab®, a suite of web-based scientific informatics applications, allowing scientists to record, manage, and share their research data​: * Notebook - Intuitive electronic laboratory notebook (ELN) optimized for collaborative models in current research environments * BioReg/ChemReg Registration - Configurable repository for registering unique chemical/biological entities and subsequent batches * Assay - Flexible system for registering assay protocol and result data * Inventory - Comprehensive tool for defining and managing chemical and biological compounds, reagents, equipment, and other items * Search - Robust decision support platform for querying, visualizing, and reporting data * Workflow - ArxLab Workflow allows users to create new work requests and to assign them to users and/or groups. The workflow management tool enables scientists to manage and prioritize all scientific projects, as well as to make procedure requests to internal colleagues and external partners. For more information, please visit our website at www.arxspan.com

Asimov's mission is to advance humanity's ability to design living systems, enabling biotechnologies with outsized societal benefit. The company is developing a synthetic biology platform from cells to software to design and manufacture next-generation therapeutics, including cell & gene therapies, through a combination of products, services, & collaborations. Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million.

Auron Therapeutics is a privately held patient-centered, platform-powered, product-driven oncology company. We are the leaders in identifying and targeting cell state to treat a range of solid tumors and hematological malignancies.

BERGis aclinical-stage,AI-powered biotechnology company taking a bold ‘Back to Biology™, approach to healthcare. By leveraging a proprietary intelligence platform – Interrogative Biology®, their goal is to map disease and develop new treatments for patients.COVID-19: Testing their technology in reducing COVID-19 patient mortality.

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solution collects and analyzes over 120 biomarkers in real time and identifies shifts that require proactive interventions. This vital innovation enables Biofourmis to offer people everywhere connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, payers, biopharma companies and patients alike, Biofourmis’ connected platform improves patient outcomes, prevents hospitalization readmissions, accelerates drug development, and closes critical gaps in care—with the goal of making science smarter, healthcare simpler, and patients healthier. Biofourmis is a global technology company enabling care delivery, with headquarters in Boston with key offices in Singapore and India. For more information, visit biofourmis.com and follow Biofourmis on LinkedIn, Twitter and YouTube.

BostonGene is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer.

BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advanced clinical stages. As BPGbio continues to expand our biobank, and the network insights that are derived from it, we anticipate more promising discoveries made with improved time and cost efficiency.

Bullseye Biosciences is a therapeutics discovery company revolutionizing drug development through robotics and evolution. Our platform operationalizes cutting-edge directed evolution technology by incorporating automation and Next Generation Sequencing. By targeting challenging drivers of human disease, we are creating life-saving medicines for cardiometabolic, inflammation, and oncology patients with the highest needs.

At CAMP4 Therapeutics, we are pioneering a novel approach to programmable therapeutics. We combine a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. Our platform’s proprietary insights enable us to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of diseases affecting millions of patients. Join us at the forefront.

Cancer diagnostic

Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas including those in metabolic disease, hematology, and immuno-oncology.

Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies. Cellino’s vision is to enable healthier lives worldwide with personalized treatments derived from induced pluripotent stem cells (iPSCs), which can serve as the basis for therapies for a host of chronic degenerative diseases, including vision loss and Parkinson's disease.

Centaur Labs is the modern data labeling solution for AI innovators across the healthcare landscape. With an expert crowd of 50k+ labelers and a gamified app to incentivize and quality-control them, our scaleable labeling methodology ensures high-quality labels in as little as 24 hours.

Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.

Their mission is to accelerate insights and outcomes for patients through leading real-world data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, healthcare providers, and medical societies.

Science has a problem. There are many suppliers and many scientists. Finding the right supply at the right price is hard, and if you're a life science company, you want to be able to get your customers the best product. We are creating a better vision for scientists to conduct science and make new discoveries. Located between two of the most prominent universities in the world, Harvard University and Massachusetts Institute of Technology, our startup has access to some of the most talented biotechnology, life sciences, and medical/health professionals in the world. https://linktr.ee/conduct_science

The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases. With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.

DeepCure is transforming the field of small-molecule drug discovery, by delivering better drugs in a faster and cheaper way. The company was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists and biologists. DeepCure does not use AI to simply generate a profile of the target candidate profile (TCP), but instead re-engineers drug discovery to deliver transformative results.

DeepHealth is RadNet's AI-powered health informatics subsidiary, created to empower breakthroughs in care delivery. The heart of its portfolio of solutions, the DeepHealth OS, is a cloud-native operating system that orchestrates all data to drive value across the enterprise. DeepHealth aims to elevate the role of the radiologist, beyond radiology and across the entire care pathway. It empowers all users across the care continuum with personalized workflows to make work easier and more meaningful. DeepHealth leverages advanced AI technologies in breast, lung, prostate, and brain health, as well as operational efficiencies to create end-to-end efficiency across the enterprise.

Dewpoint is the first company to apply an emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Novo Nordisk, Evotec and Chemify. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into breakthrough treatments for diseases previously considered untreatable. 

As a nonprofit engineering innovation company, Draper serves our nation's interests and security needs; advances technologies at the intersection of government, academia, and industry; cultivates the next generation of innovators; and solves the most complex challenges. Multidisciplinary teams drawn from a broad and deep talent pool of 1,200 engineers and scientists collaborate to develop first-of-a-kind solutions. Our unbiased approach enables us to focus on our customers' needs and to deliver new capabilities to them.

Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy.Using machine learning and quantitative high-throughput in vivo experimentation, they are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

Elucid is a Boston-based medical technology company using histology-validated software to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid's CTA analysis equips physicians with critical information designed to enable precision medicine. Elucid is the first non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall. Elucid's unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs.

At EnClear Therapies, we are combining Bioscience & Med-tech expertise to develop solutions that improve and extend the lives of patients with CNS disease. The team at EnClear is developing systems and medical interventions that Access, Recirculate & Modify CSF for: › Targeted removal of toxicity from CSF correlated to neurodegenerative disease progression. › Continuous localized delivery of therapeutics & monitoring of CSF to ensure effective and personalized therapy.

Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has designed its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs harness the ability of DUBs to regulate proteins. By leveraging this natural cellular mechanism to enhance protein function, Entact is expanding the universe of treatable diseases.

Fable Therapeutics Inc. was founded with a conviction to revolutionize drug discovery through the purposeful integration of AI techniques. ‍ Our cross-functional team of ML scientists and drug hunters collaborate to design novel medicines with expanded therapeutic potential. ‍ With this passion and vision, we’re designing the future of drug discovery.

FDNA uses facial analysis, deep learning and artificial intelligence to transform big data into actionable genomic intelligence to improve diagnostics and therapeutics.

Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple transformative human health and sustainability products. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures. The current Flagship ecosystem comprises over 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.

GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCells™ by tailoring cells for specific diseases. The core technology of GCTx was conceived, invented and perfected in Professor George Church's lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.

Generate:Biomedicines is a new kind of therapeutics company—existing at the intersection of machine learning, biological engineering, and medicine—pioneering generative biology to create breakthrough medicines. Through The Generate Platform, we are able to expand the breadth of technical possibilities in order to fundamentally change the way medicines are made.

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Its capacity to develop high potential assets, from early-stages to late development and pre-commercialization stages, is illustrated through the successful 52-week readout of its Phase 3 trial (ELATIVE®) evaluating elafibranor in Primary Biliary Cholangitis (PBC). Today, GENFIT has a diversified R&D pipeline covering several therapeutic areas: five programs in acute on chronic liver failure (ACLF) are in clinical stages (Phase 2) and pre-clinical stages, including hepatic encephalopathy (HE), one of the main complications of ACLF; a Phase 2 clinical program targeting cholangiocarcinoma; and a preclinical program targeting urea cycle disorders (UCD) and organic acidemias (OA). GENFIT’s pipeline also includes a diagnostic franchise focused on Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis or NASH) and ammonia. GENFIT has facilities in Lille and Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s largest shareholders and holds 8% of the company’s share capital.

Based in Sudbury, MA., Gentuity is a commercial-stage medical technology firm dedicated to developing next-generation intravascular imaging devices capitalizing on today's best-in-class technologies. Gentuity was founded on the principles of advancing patient care, improving outcomes, and expanding the utility of intravascular procedural guidance tools in the realm of cardiovascular disease. The Gentuity High-Frequency OCT Imaging System is the first commercially available OCT imaging system to deliver Total Vessel Imaging with the first 1.8F micro-imaging catheter. Gentuity and its' next-generation platform are paving the way for transformation in the intravascular imaging world. Designed to support the growing needs of the imaging industry, the platform incorporates AI and machine learning with the intention of creating "collaborative intelligence" to enhance ease of use and procedural success.

At Ginkgo, we use biology to grow the future. Companies across industries leverage our platform to design, develop, and optimize products for a breadth of commercial applications. We help our partners grow key ingredients for vaccines, crops that rely less on fossil fuel-based fertilizers, plant-based meat that tastes like the real thing, materials for the next generation of circular fashion, and so much more. We know our unique experiences, ideas, and perspectives are essential to our success and enable us to make biology easier to engineer and ensure equitable distribution of the benefits of our platform. As such, we seek to ensure that DEI is in our DNA, continuing to grow an inclusive culture and diverse workforce. Let's make biology easier to engineer and join our team.

Glytec's industry leading SaaS platform, trusted by 350+ hospitals, empowers collaborative diabetes management and insulin dosing, improving patient outcomes, reducing readmissions, and streamlining workflows while delivering a 6-8x ROI. The first-ever FDA-cleared cloud-based insulin management software is EMR-integrated, easy to set up, and validated by 106 patents and over 100 publications. The Glytec Glucommander® solution, with clinical decision support, workflow alerts, patient monitoring, at-risk patient identification, and AI-driven analytics, is supported by a mission-driven team dedicated to helping healthcare leaders, clinicians and patients promote health equity and improve diabetes outcomes from hospital to home. We are on a mission, join us. For more information, follow Glytec on X (@Glytec) or visit www.Glytec.com.

GNS Healthcare is a healthcare analytics company that specializes in precision medicine and biomedical research through advanced health data analysis.

At Harbinger Health, our mission is to change the cancer paradigm by taking a proactive approach to cancer detection and prevention. We envision a future where cancer is no longer a life-altering event, but a routine health problem that can be addressed with early intervention. To achieve this, we have developed proprietary solutions for cancer pre-emption, starting with blood-based tests that can detect cancer before it even becomes visible. By identifying biological programs that are the root cause of cancer, we can enable early-stage and pre-disease identification, leading to truly personalized and effective cancer care for everyone. With Harbinger Health leading the way, we believe that a cancer-free future is not only possible but within reach, for everyone.

HelixNano is building the world's most advanced mRNA platform to enable previously impossible applications across human and non-human biology

HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. In addition, HiFiBiO Therapeutics aspires to benefit patients through open-innovation partnerships with industry and academia. For more information, please visit www.hifibio.com.

We’re an innovative medical technology company whose purpose is to enable healthier lives everywhere, every day. While we discover and develop groundbreaking products and services that benefit everyone, we are especially passionate about those that advance women’s health and well-being. This allows us to be a company that prospers, grows and empowers women to experience healthier lives. None of this would be possible without the talent, skills and aspirations of our employees. Their expertise and dedication to developing and sharing more robust, science-based certainty drives our increasingly global presence, as well as a pipeline that responds to the unmet health and wellness needs of women, families and communities. What powers our growth across Breast & Skeletal Health, Diagnostic Solutions, and GYN Surgical Solutions is also what differentiates us: the exceptional and clinically proven ability of our products to detect, diagnose and treat illnesses and other health conditions earlier and better. This clinical superiority creates high expectations, which we fulfill by always challenging ourselves to improve health through better technology, education and market access. Our goal is to minimize doubt and maximize the confidence our customers and their patients have in their decisions and diagnoses. We work toward this goal every day, always aware that in an increasingly complex and competitive global environment, we must continually earn the trust of our customers and their patients. By focusing on women’s health while still delivering health benefits to everyone, we are setting a new standard of excellence that is strengthened by purpose, driven by passion and brought to life by our promise of more certain early detection and better health outcomes. To view our community guidelines, visit: www.hologic.com/social-media

Inspired by nature’s ability to regulate protein function to restore health, HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways. Unlike conventional drug discovery, which focuses on targeting the active sites of proteins, HotSpot has developed a technology platform to uncover nature’s privileged regulatory hotspots – pockets remote from the active site that are critical to protein function. Our team is designing novel therapies directed at regulatory hotspots, allowing us to treat diseases with limited or no known treatment options. Hotspot medicines are superior to conventional therapeutics given their exquisite selectivity, potent in vivo pharmacology and attractive drug-like properties.

AI-powered fertility care

Inari is the SEEDesign™ company, using new breeding technology to push the boundaries of what is possible by designing nature-positive seeds for a more sustainable global food system. A combination of AI-powered predictive design and a pioneered multiplex gene editing toolbox enables us to unlock the full potential of seed and advance critical solutions with broad applications for growing more food with fewer resources.

InfoBionic.Ai's MoMe® ARC system empowers physicians with control to transform the efficiency with which they manage cardiac arrhythmia detection and monitoring processes for their patients. Leveraging a comprehensive, Cloud-based remote patient monitoring platform – the first and only of its kind – we deliver on-demand, actionable monitoring data and analytics directly to the physicians themselves. The MoMe® Kardia 3-in-1 device streams continuous ECG, respiration, and motion data to the Cloud for analysis, and delivers automated reporting to an iPad and or a web-based portal where physicians can access and interact with the data they need, in the detail they want – anytime, anywhere.

Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.

Intus Bio is using its proprietary high-resolution, high-throughput assay and analysis technology to identify bacteria and deliver answers about the microbiome, with unprecedented detail, accuracy and scale. The company is powering groundbreaking research, discovery and services with clients and partners across the global pharmaceutical, diagnostic, and testing industries; is active in health, agricultural, and environmental fields; and continues to develop new and innovative partnerships, technologies, and applications.

Invicro is a company in the medical imaging and biotechnology industry that specializes in imaging services for pharmaceutical and life sciences companies.

Javelin Biotech makes predictive drug discovery platforms that merge human biology with computational biology to improve the speed and predictive power of preclinical testing. The Javelin platform combines human tissue chips, also known as organs-on-chip, with translational software to provide predictive solutions for drug discovery.

Kailera Therapeutics (Kailera) (previously Hercules CM NewCo) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health.

Kernal creates mRNA therapies to cure severe diseases including cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space.

KiraGen Bio is pioneering the next wave of cancer treatment through AI-driven, multiplex gene-edited CAR-T cell therapies, targeting the challenging realm of solid tumors. Despite the transformative success of cell therapies in hematologic cancers, solid tumors — which constitute the majority of cancer cases — have remained elusive to current treatments due to their complex tumor microenvironment (TME). Our mission is to breach this final frontier, leveraging our proprietary AI platform and combinatorial gene editing to design CAR-T cells capable of overcoming the immunosuppressive barriers of the TME. Founded on the belief that every cancer patient deserves a chance at a cure, KiraGen Bio combines the latest in biotechnology and computational science to bring innovative therapies from the lab to the clinic. Our team, comprised of experts in oncology, immunology, gene editing, and artificial intelligence, is dedicated to creating effective, durable treatments for solid tumors. KiraGen Bio stands at the intersection of innovation and hope, where cutting-edge science meets the urgent need for more effective cancer treatments. Our integrated approach spans from discovery through clinical development, embodying a commitment to excellence, patient-centricity, and the relentless pursuit of curing cancer. Join us as we work to transform the landscape of cancer therapy and bring new hope to millions of patients worldwide.

Korro Bio was founded to turn extraordinary scientific insights into life-altering new treatments for patients. We harness the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Our mission is to rewrite the future for patients living with debilitating disease by repairing the underlying genetic cause.

We are building next-generation products to transform how food testing is done, providing fast, accurate, and affordable testing solutions for consumers and businesses so they can test anytime and anywhere. At its core, Labby is an AI-powered spectrometer. It is portable and super versatile. It combines the power of optical sensing and machine learning so it can be used in many industrial applications beyond food.

Lattice Automation provides complete solutions to fundamentally change the way that biological designs are conceived, designed, physically created, and managed. Our technology builds upon state-of-the-art techniques in computer science, electrical engineering, and bioengineering. We're hiring!

Layer Health is a healthcare AI company spun out of MIT and backed by GV (Google Ventures), General Catalyst, MultiCare Health System and Froedtert Health. We are solving the information problem in healthcare.

Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Based on MIT research, Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device.

Manifold Bio is a therapeutics company with an unprecedented advantage in engineering precision biologics. We have developed the world’s first high-throughput in vivo drug design platform, enabled by a novel protein barcoding technology and other innovations at the interface of molecular biology and compute. Our mission is to make the best life-saving drugs available to patients as quickly as possible. We’ve brought together a team with unique expertise in library-guided protein engineering combining DNA synthesis, sequencing, and advanced bioinformatics and machine learning. We’re growing and we’re looking for those who are excited about the potential of our novel approach to engineering biology.

Guided by the needs of our patients and their families, Massachusetts General Hospital aims to deliver the very best health care in a safe, compassionate environment; to advance that care through innovative research and education; and, to improve the health and well-being of the diverse communities we serve. Visit our careers page! http://www.mghcareers.org

Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information, please visit www.matchpointtx.com.

MeMed is a leading med tech and bio-convergence company, having developed innovative diagnostic host immune response testing methods that address complex clinical dilemmas and improve patient outcomes. Our mission is to translate the complex signals of the immune system into simple diagnostic insights that transform the way we treat infectious diseases and inflammatory disorders – at the right place and the right time.

The METiS platform (AiTEM) combines state-of-the-art AI data-driven algorithms, mechanism- driven quantum mechanics and molecular dynamics simulations to calculate Active Pharmaceutical Ingredient (API) properties, elucidate API-target and API-excipient interactions, and predict chemical, physical and pharmacokinetic properties of small molecule and nucleic acid therapeutics in specific microenvironments. This enables efficient lead optimization, candidate selection and formulation design. Founded by a team of MIT researchers, serial entrepreneurs and biotech industry veterans, METiS develops and in-licenses novel assets with high therapeutic potential that could benefit from its data-driven platform.

The Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts. MIT is devoted to the advancement of knowledge and education of students in areas that contribute to or prosper in an environment of science and technology.

MOMA Therapeutics is a clinical-stage, next-generation precision medicine company dedicated to targeting highly dynamic proteins that underlie human disease via a small molecule approach, utilizing its proprietary KNOMATIC platform. The platform was designed to exploit key vulnerabilities inherent to all dynamic proteins, namely their dependence on well-coordinated, stepwise changes in protein conformation. By focusing on genetically validated targets with high translation potential MOMA is rapidly advancing its pipeline toward responses in the clinic. In January 2024, MOMA announced a five-year discovery collaboration with Roche focused on critical cancer dependencies. We are unapologetically scientific, and we know this will help us achieve our mission to get new medicines to people in need. We’ve removed the bureaucracy and believe having a teammate’s back is critical to our success. You see, MOMA isn’t your typical biotech company. We are drug discovery professionals, industry specialists and scientific experts. More importantly, we’re collectively unstoppable.

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn’s disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is based in Boston, Massachusetts.

We develop AI and wet-lab technologies that enable the rational design of developable, selective, and functional drugs against previously undruggable targets. To maximize the patient impact of our platform, we collaborate with leading pharmaceutical companies, including AstraZeneca, Bristol Myers Squibb and Takeda, to expand their pipelines with high-quality drug candidates. If successful we could double the number of disease-relevant drug targets the industry advances for drug development. Since launching in 2021 we have raised $37 million with the backing of leading investors, including Radical Ventures, Khosla Ventures and Zetta Venture Partners. Our technical team is based in Cambridge, Massachusetts and continues to recruit top machine learning and synthetic biology talent. For more information check out the Careers section of our website at www.nabla.bio.

Nanite is a next-generation non-viral gene delivery company developing a new class of programmable polymer nanoparticles for a range of modalities and indications. The company’s AI-driven platform, SAYER, combines cutting-edge high-throughput experimental and computational methods to design fit-for-purpose delivery vehicles delivering a broad range of genetic cargoes with tissue specificity.

Nereid starts with approaches to see and measure the biomolecular forces driving phase separation, amplifying insights with machine learning, and accelerating translation with cell biology and medicinal chemistry. Nereid’s platform uses physics to discover therapeutics that can modify the phase behavior of livingcells.

We are Nested Therapeutics, a biotech company inspired by service and driven by a desire to make a meaningful impact. We are creative innovators who challenge our own assumptions as we strive to find new, overlooked areas of opportunity to design therapeutics for a perfect fit. We embrace diverse perspectives and experiences in a space for everyone to add value and be valued in return, with the purpose of building solutions together while having fun doing it. United through our common vision for the future of precision medicine and our shared values of service, humility, impact, invention, and connection, we’re determined to dramatically expand the reach of precision medicine and make first- and best-in-class precision oncology treatments available to a larger population.

While our healthcare system has increasingly embraced virtual health in many areas to accelerate access to care, in-person care for patients with cognitive conditions remains the status quo - but Neuroglee Health is making virtual cognitive care a reality. We partner with medical groups to serve as your practice's virtual cognitive care extension – enabling you to provide immediate access to evidence-based care for patients with cognitive disorders and highly coordinated, guided support for the caregivers they rely on. Through our virtual care model, which we developed in collaboration with Mayo Clinic, Neuroglee Health is leaning in to disrupt the status quo. Our partners gain timely access to our team of expert multidisciplinary specialists and powerful, award-winning digital tools: a patient app, care partner app, and clinician dashboard, which optimize patient and caregiver engagement, deliver actionable data-driven insights, and enable coordination across the patient's extended care team. When combined, Neuroglee Health helps patients improve cognition, enhance quality of life, and prolong patient independence, while reducing provider and caregiver burnout. We are on a mission to improve the lives of individuals with cognitive conditions and their loved ones. Join us at www.neuroglee.com.

nference leverages the top academic minds, world-class researchers, and real-time access to multimodal, patient-level data to accelerate drug development innovation, generate evidence, and improve clinical trial processes. nSights, our flagship software platform, delivers the most comprehensive biological and clinical insights into patient care.

Novopyxis is a biotechnology company that specializes in the development of therapeutics and medical devices using proprietary mathematical algorithms for drug validation across various models.

Develops a diagnostics platform.

At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine. In response to recent recruitment fraud, visit our Careers page to verify all job opportunities and read our guidance on this topic: https://odysseytx.com/careers/

Developing metabolomics assays and machine learning algorithms to produce “Biomarkers of Response” (BoR) that differentiate drug responders (R) from non-responders (NR).

Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature’s operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

OmniGuide's corporate culture has grown from the roots of an innovative idea from MIT to a global company that has successfully adapted to changes in the market. INSPIRATION Our purpose is to help reduce complications, every day. We achieve this with our creative energy and enthusiasm for fresh ideas. Our motivation is to continually remind ourselves that when we get up in the morning, patients who need our therapies are counting on us. EXCELLENCE The pursuit of excellence lies at the heart of everything we do. We are builders, redefining what it means to support great outcomes. We have the courage to think different and will ensure that OmniGuide remains committed to ideas that benefit patients and their outcomes.

Orbital Therapeutics is building a first-in-kind platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of RNA-based medicines to treat disease in humans.

Orthogon Therapeutics is a drug development company focused on designing innovative antivirals and anti-infectives. Their initial focus is on treating BK and JC polyomavirus infections in transplant patients.

Overjet is the world-leader in dental AI. Founded by experts from MIT and Harvard University, Overjet builds artificial intelligence that helps dental organizations give patients the highest quality of care. Our FDA-cleared technology is the first objective standard for making oral health decisions — so that dentists can detect pathologies with precision and educate patients with confidence.

PhaseV is leveraging cutting-edge algorithms such as reinforcement learning and causal ML for adaptive trial design and closed-loop execution, in order to improve trial success rate while maximizing resource and time efficiency. Our novel methodology and advanced technology also enable the detection of hidden signals in data while analyzing clinical trial results and extracting actionable insights.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology makes immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. Phio was co-founded by Nobel Laureate Craig Mello, who was awarded the Nobel prize in 2006 for his discovery of RNAi, which has broad therapeutic applications. Our founders opened up a whole new field of biology when they discovered RNAi, and we continue their pioneering efforts today through our work with INTASYL. We’re committed to discovering and developing innovative cancer treatments for patients, creating new pathways for a cancer-free future. For additional information, visit the Company's website, www.phiopharma.com. #INTASYL #siRNA #RNAi #Phio #immunooncology

Praesidia Biotherapeutics is built with the vision of being a patient focused and clinician driven drug development company championing unmet clinical needs. Praesidia's proprietary first in class Tunable Linker Technology is revolutionizing the ways to maximize.

Pramana, Inc., is a health technology company reimagining digital pathology through its autonomous AI-enabled whole-slide imaging solutions. Built upon extensive industry experience and patented technological innovation, Pramana enables pathologists and physicians to accelerate precise diagnosis with reduced manual intervention, minimizing human errors and improving operational efficiency. Pramana is headquartered in Cambridge, Mass., with R&D and manufacturing sites in Bangalore, India; Rochester, Minn.; and Toronto, Canada.

We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test to uncover actionable disease-defining transcriptional biology.  Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma.  By partnering with developers of new medicines and advancing our own diagnostic tests, we're working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that's precise to the biology of their disease.

PrecisionLife is the clinical-stage precision medicine company for complex chronic diseases. Creating better diagnostic tools and more personalized treatment options for patients with unmet medical needs. Our analytics and AI is unique in its understanding of causal disease biology. Identifying biomarkers to stratify patients by molecular mechanism of either their disease or drug response and link individuals to the drug targets, trials and treatments that will benefit them. With these insights we significantly increase the probability of success throughout the biopharma and healthcare value chain. Accelerating, informing and de-risking drug discovery and clinical development, building highly predictive diagnostics, and in launching more personalized and preventative medicines. To learn more, visit precisionlife.com.

Predicta Biosciences is a precision oncology company integrating cutting edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Predicta's diagnostic product portfolio removes the burden of bone-marrow biopsies, through small blood-based samples, and enables best-in-class treatment decision-making for immunotherapies. Utilizing the data from the diagnostic platform, Predicta has an in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development.

ProFound Therapeutics is pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines. The company’s ProFoundry Platform uses state-of-the-art protein detection technologies to systematically identify and validate proteins and dissect their therapeutic potential. The result is an ever-expanding database of tens of thousands of novel proteins, including their connectivity, functionality, and roles in health and disease. ProFound Therapeutics was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.

Prologue is designing powerful new medicines by unlocking the viral proteome. The company’s state-of-the-art DELVE™ Platform systematically identifies and evaluates viral proteins and their unique features for their potential to precisely regulate human physiology. By co-opting viral evolution, Prologue is expanding the functional boundaries of proteins encoded by the human genome to create new programmable medicines. Prologue was founded by Flagship Pioneering in 2021.

Prudentia Sciences, a Cambridge based technology company, is dedicated to accelerating drug pipelines and maximizing return on investment, envisioning a future where healthcare innovations reach their full potential. Prudentia’s platform enables comprehensive due diligence and valuation of drug assets.

Quiver is a technology-driven company established to create transformational medicines for the brain while simultaneously uncovering new biology and novel, effective drug targets. Using advanced single cell imaging and multi-omics, we are building the world's most information-rich neuronal insight map "Genomic Positioning System" through state-of-the-art proprietary engineering and AI/ML approaches.

Quantori is the end-to-end data, technology, and digital services partner of choice for leading biopharma and healthcare organizations across the globe. We develop cutting-edge data and technology systems, applications, and infrastructures for biotech, pharmaceutical, and healthcare companies to accelerate drug discovery and improve patient outcomes. Our innovative approach harnesses the power of data engineering and informatics, machine learning, emerging technologies, and cloud expertise to bridge the gap between meaningful data and patient success, supporting every phase of the drug development process. Quantori also boasts a growing healthcare business that helps organizations optimize volumes of complex data sets to drive data to knowledge, knowledge to actionable insights, and insights to value. Quantori’s data scientists and informaticians understand the nature of data at a granular level, which is required for powering the future of precision medicine. • 20+ Years Serving the Life Science & Healthcare Sectors • Deep Domain Expertise • Over 800 experts including scientists, software engineers, data scientists • Blue-Chip Roster of Biopharma Clients • 1,500+ Digital IT Projects Contact Quantori today to learn how we can help accelerate your innovation pipeline through the power of data and digital IT. Website: www.quantori.com Email: contact@quantori.com Twitter: @Quantori_USA

Quris-AI is an artificial intelligence innovator that is disrupting drug development. Its machine-learning bio-platform better predicts which drug candidates will safely work in humans, avoiding tremendous costs of failed clinical trials. Quris-AI is led by a track-record team of top scientists and strategic investors. Its first AI-based drug is now prepping for clinical testing.

Collaborative robots have reshaped automation by enabling a wide spectrum of new applications in different industries – but a significant dexterity gap still remains even with these robots. Manipulation of delicate, fragile, or brittle items is still out of reach for robots. Inspired by our human fingertips which provide unmatched dexterity, we have set out to reduce this gap by adding tactile sensing similar to the sensing in our fingertips to enable robotic manipulation of more delicate items. Introducing the Tactile Fingertip. Ras labs has combined material science innovation with data science and precision engineering to provide the first state of the art, Tactile Fingertip for robotic gripper fingers. Our sensor is based on our patented Electroactive Polymer which can be fabricated in many configurations. Both squishy and a level of firmness. Think our revolutionary technology could help your business? Send us a message. We'd love to chat!

Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, our approach combines unprecedented computational power with leading-edge experimental approaches across the fields of structural biology, biophysics, chemistry and biology. By applying these insights, we believe we have a differentiated approach to drug protein targets based on their motion, enabling us to select and advance unique product candidates that can be developed into novel therapies for patients. Located in Cambridge, Massachusetts, our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you're creative, collaborative and passionate about making a difference in the lives of patients, join us!

Reprieve Cardiovascular, Inc. is developing innovative and groundbreaking therapies that aim to improve the lives of more than 25 million heart failure patients around the world. Reprieve is bringing intelligence to decongestion management to safely accelerate fluid removal for heart failure patients. In 2022, Reprieve initiated the FASTR Trial (pilot study) to compare decongestive therapy administered by the Reprieve Decongestion Management System to Optimal Diuretic Therapy in the treatment of patients diagnosed with acute decompensated heart failure. Reprieve is a privately held medical device company, headquartered in Milford, Massachusetts, USA.

ReviveMed is an MIT spinout AI-based metabolomics platform for precision medicine in oncology and cardiometabolic disease. Blood metabolites, e.g., glucose and cholesterol, are crucial direct readouts of drug response and have been associated with disease outcomes, yet under-explored, as <5% of them are characterized. Our patented AI platform characterizes 20 times more metabolites than current platforms, pioneering the development of blood-based metabolic tests of drug response and safety. The unprecedented amount of metabolomics data has enabled us, for the first time, to develop pre-trained foundation models for metabolomics to simulate treatment outcomes and pave the way for the future of precision medicine.

Rubix LS: The Health Outcomes Architect At Rubix LS, we drive innovation in clinical research, drug development, and public health by combining cutting-edge science, real-world data, and inclusive patient engagement. Our work is structured around three core pillars: 🔹 Investigator-Led Research – We conduct our own research and develop targeted solutions to accelerate new therapies and improve health outcomes. 🔹 Clinical Research Services – We collaborate with biotech, pharma, and life sciences companies to manage clinical trials, support regulatory submissions, and enhance patient diversity in research. Our work is powered by 18M patient data sets and 369M patient data points. 🔹 Government & Public Health – We partner with federal agencies and public health organizations to develop policies, improve disease surveillance, and advance health equity through data-driven solutions. Leveraging Environmental & Geographic Insights To better understand health risks and intervention strategies, we integrate: ✅ DoE data to analyze long-term environmental exposures. ✅ USDA data to study the impact of food and nutrition on health. ✅ Heat Sink data to model cancer risk and environmental disease patterns. At Rubix LS, we don't just conduct research—we build pathways to better health by ensuring therapies are developed, tested, and delivered with precision, equity, and impact. 🔗 Learn more at our website.

We work at the frontier of programmable medicines. We power our bioplatform and product candidates by harnessing evolution and AI. We operate with purpose and urgency on behalf of people everywhere. We aim to generate life-changing impact for the world.

SaponiQx is a cutting edge bio-pharmaceutical company with a vision of protecting the health of populations worldwide. We seek to enable the development of safe and effective vaccines through the expansion of access to saponin based adjuvants. Contact Us! communications@saponiqx.com

Sapphiros, backed by Neoenta and KKR, is a privately held consumer diagnostic portfolio company. The Sapphiros portfolio includes novel sample collection, next generation diagnostics, computational biology, and printed electronics to help consumers access important diagnostic results globally. Knowing Now Moves Us™ Knowledge empowers us to navigate through life's choices and decisions. With solutions that provide real-time, definitive results; at Sapphiros we work together to help global communities act on these insights with confidence.

Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don’t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.

We are The Machine Learning Immunology Company. Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics drug discovery and development process. Using our IMPACT™ platform, we are fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies for patients. Seismic Therapeutic has an emerging pipeline of novel approaches to address adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub.

Founded by world-class researchers, clinicians, and thought leaders from Massachusetts General Hospital and Harvard University, Sensorium Therapeutics is a biotechnology company leveraging cutting-edge chemistry, neuroscience, and machine learning to develop nature-derived psychoactive medicines for mental health. Inspired by the real-world human benefits of plants and fungi, Sensorium’s groundbreaking Biodynamic Discovery Platform leverages cutting-edge chemistry, neuroscience, and machine learning to reproduce, adapt, and enhance targeted molecules to elevate their utility as modern medicines that can deliver transformational benefits to patients around the world. Visit sensorium.bio to learn more.

Somite.ai is developing AI foundation models for human stem cells to drive novel cell therapies at scale. We take a full-stack approach—generating data at 1,000x lower cost, training large-scale models with unmatched predictive power, and using these models to discover, refine, and optimize high-impact applications in cell therapy. Our founding team includes repeat AI entrepreneur Dr. Micha Breakstone (Chorus.ai, acquired for $575M), the Head of the Fundamental AI Group at MIT (pioneered the foundational research on scaling laws), and four Harvard Medical School professors and National Academy of Sciences/Medicine members, including the Chair of the Genetics Department at HMS. Based in Boston and launching operations in January 2024, Somite has raised over $11M in pre-seed funding

Somite.ai is a venture-backed company aiming to become the OpenAI of stem cell biology, developing AI foundation models to produce human tissue for cell therapies at scale for diseases such as diabetes, obesity, and muscular dystrophies. Somite's AI platform, AlphaStem, fuels a virtuous cycle: It enables new cell therapies, generating massive data that further improve the platform, empowering even faster therapy creation with broader applications. The company's pipeline includes the promising SMT-M01 program for Duchenne muscular dystrophy (DMD) and the SMT-B01 program for metabolic disorders. Incorporated in Oct. 2023, Somite.ai has raised over $10m to date.

SpectraWAVE, located in Bedford, Mass., is a privately held medical device company founded in 2017 to provide unrivaled optical and computational insights to improve the treatment and outcomes for patients with coronary artery disease (CAD). CAD, the buildup of plaque in the wall of the arteries that supply blood to the heart, affects 18.2 million adults age 20 and older. In CAD patients that undergo percutaneous stent placement, it is estimated that one in five patients experience adverse events within two years. SpectraWAVE’s state of the art HyperVue™ Imaging System combines next generation DeepOCT™ images and near infrared spectroscopy (NIRS) with workflows optimized for the cardiac catheterization lab. The HyperVue Imaging System is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The NIRS capability of the system is intended for the identification of patients and plaques at increased risk of major adverse cardiac events. For more information and complete indications for use, please visit www.spectrawave.com.

Advancing cerebrovascular care through groundbreaking neuro intravascular imaging and AI technologies.

Sumitomo Pharma America (SMPA) is a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need in psychiatry and neurology, oncology, urology, women’s health, rare disease, and cell and gene therapies. SMPA was formed through the consolidation of Sumitomo Pharma’s U.S. affiliate companies including Sunovion Pharmaceuticals, Inc., Sumitomo Pharma America Holdings, Inc., Sumitomo Pharma Oncology, Inc., Sumitovant Biopharma, Inc., Myovant Sciences, Inc., Urovant Sciences, Inc. and Enzyvant Therapeutics, Inc. SMPA is a Sumitomo Pharma company.

Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP.

Syncell is a life science tools company revolutionizing proteome and biomarker discovery. Imagine that you have a subcellular “pickable” microscope to let you isolate and identify proteins at a specific location you like under the microscope. Syncell’s groundbreaking Microscoop platform enables hypothesis-free subcellular spatial proteomics with high sensitivity and specificity. Researchers are able to use Syncell Microscoop to discover proteins novel at specific locations of interest from cell and tissue samples. This pioneering technology revolutionizes how novel molecular mechanisms can be identified and how novel biomarkers can be revealed for diseases.

Tenza reprograms symbiotic bacteria from the human microbiome to administer medicines directly to the organs they naturally inhabit.

Thymmune is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease. The company's cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale. The company is developing a pipeline of therapies to treat immunodeficiencies, transplant related, and autoimmune diseases. Thymmune is based in Cambridge, MA.

Totus Medicines is applying revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases.

TRIANA Biomedicines is a venture-backed biopharmaceutical company leading a transformative approach to discover and develop novel small molecules to treat disease. Our technology enables us to identify molecules that promote the interaction between a target and another protein in a way that alters the fate or function of the target protein. These innovative “molecular glues” allow us to treat disease in entirely new ways by pursuing highly disease relevant targets that have long been considered undruggable or are inadequately addressed.

With almost 30 years of expertise, a best-in-the-business team and unrivaled access to data and analytics, Trinity Life Sciences is a modern partner to companies in the life sciences industry. Trinity combines strategy, insights and analytics to help life science executives with clinical and commercial decision-making. We serve over 300 pharmaceutical, biotech and medical device clients, helping them develop the right drugs and devices for today’s market and optimize them once in market. In 2023, the company worked on 75% of all new drug launches and provides ongoing, in-depth, high value thought leadership that helps shape the industry. With a diverse staff of over 1,200 employees and 11 global offices across the U.S., Europe and Asia, Trinity continues to grow both organically and through acquisitions. These acquisitions included BluePrint Research Group, CBPartners, TGaS Advisors, Bell Canyon and D Cube Analytics, the latter of which dramatically leap-frogged Trinity to the leading provider of go-to-market analytics and AI to biopharma companies. Trinity has also entered into a transformative partnership with Bain & Company that has strategically advanced Trinity’s mission to revolutionize the pharmaceutical commercial model. Ultimately, we know that every decision our clients make impacts a life, and when we help our clients achieve their goals, the world benefits.

Universal Diagnostics S.A. (UDX) is a Spanish in-vitro diagnostics company developing minimally-invasive, blood-based solutions for detecting cancer early when treatment options are more plentiful and survival rates are still high. UDX believes that the best way to fight against cancer is by detecting it early. The UDX diagnostic platform is designed to detect various cancer types, e.g. colorectal, prostate, liver, pancreatic lung, breast cancer (>50% of all new cancer cases p.a.) via one simple blood test. The assays rely on a curated set of proprietary methylation marker panels; a simple blood sample collected as part of a routine check-up, can be processed at a reference laboratory or hospital using standard equipment and then uploaded to the UDX Cloud for final algorithmic analysis. UDX's first marker panel is a colorectal cancer screening test. The test identifies individuals who need to be referred for colonoscopy. Colorectal cancer is the 3rd most frequent cancer and 2nd deadliest cancer worldwide. The challenge is that colorectal cancer is mostly detected in late stages, with significantly decreased survival rates (11% survival rate in stage IV vs. 85% survival rate in stage I). To develop the test and execute its R&D and operations, UDX partners with international research institutions, hospitals, universities, and biobanks around the globe.

Valo is a technology company built to transform drug discovery and development using large-scale data and AI-powered computation. Valo aims to ful­ly inte­grate human-cen­tric data across the entire drug devel­op­ment life cycle into a sin­gle uni­fied archi­tec­ture, there­by accel­er­at­ing the dis­cov­ery and devel­op­ment of life-chang­ing drugs while simul­ta­ne­ous­ly reduc­ing costs, time, and fail­ure rates. The company’s Opal Com­pu­ta­tion­al Plat­form™ is an end-to-end drug dis­cov­ery and devel­op­ment plat­form with a uni­fied archi­tec­ture designed to trans­form data into valu­able insights that may accel­er­ate dis­cov­er­ies and enable Valo to advance a robust pipeline of pro­grams, ini­tial­ly focused on car­dio­vas­cu­lar meta­bol­ic renal, oncol­o­gy, and neu­rode­gen­er­a­tive dis­ease.

Variantyx is a technology-driven precision medicine company providing state-of-the-art diagnostic solutions for the rare genetic disorders and reproductive genetics markets, and treatment optimization in oncology. Our unique, comprehensive testing platform uses whole genome sequencing to identify all major genetic changes from a single sample. The results empower patients and providers with information that can rapidly end the challenging diagnostic search, optimize treatment, and improve quality of life. We are a diverse, multinational company that embodies professionalism, transparency, tenacity, and respect. See more with us: www.variantyx.com/.

Velsera connects healthcare and life sciences to reveal the true promise of precision medicine — a continuous flow of knowledge between researchers, scientists, and clinicians around the world, fueling innovation and creating insights that radically improve human health. Our goal is to use data to radically improve healthcare globally and create value through multiomics and insights. If you’re interested in learning more about Velsera, please follow us and visit our website at velsera.com! Looking for someone to get in touch with? Please email hello@velsera.com

VideaHealth is on mission to transform dentistry through artificial intelligence. Rooted in AI research conducted at Harvard and MIT, VideaHealth’s FDA-cleared dental AI platform is proven to increase diagnostic accuracy, grow treatment plan values, and improve case acceptance rates. With the largest and most diverse data set in the market, VideaHealth is the partner of choice for the nation's leading DSOs - and is trusted by dentists, hygienists and patients. Backed by leading venture capital firms Spark Capital, Zetta Venture Partners and Pillar VC, VideaHealth is headquartered in Boston.

Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Our proprietary technology platform enables the design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets. Applying this technology to disease targets that are not adequately addressed by traditional therapeutic approaches, we are developing a robust pipeline of novel therapies for patients with unmet needs. Our most advanced program is in Phase 2 clinical development. In addition, Visterra has established a number of partnerships to progress novel antibodies engineered to treat significant diseases with limited treatment options.

The Watershed Omics Bench provides biologists and bioinformaticians a unified workspace to design, execute, and iterate through multi-omics analyses on the cloud

At the Wyss Institute, we leverage recent insights into how Nature builds, controls and manufactures to develop new engineering innovations - a new field of research we call Biologically Inspired Engineering. Our scientists, engineers and clinicians, who come from Harvard's Schools of Medicine, Engineering, Arts & Sciences, Design, and Education as well as 12 collaborating academic institutions and hospitals, work alongside staff with industrial experience in product development to engineer transformative solutions to some of the world’s greatest problems. By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.

X-Chem is your preferred partner for innovative small molecule discovery. Synergizing DNA-encoded chemical library technology, discovery chemistry, and artificial intelligence, we provide pharmaceutical and biotech companies complete, seamless solutions for challenging, high-value therapeutic targets. With 80% success rate in identifying functional hits, ~100 programs licensed, 4 clinical candidates since 2021, and our technologies proven in ~30 challenging target classes, we are committed to helping create molecules that will improve human health. We work closely with our partners at any stage of early drug discovery, including screen-to-hit, hit-to-lead, lead optimization, and/or candidate identification to maximize project success. Our extensive expertise guarantees quality results, bringing our partners’ novel therapy closer to the clinic. Our clients benefit from flexible access to our innovations, including integrated project support, screening and follow-up, or access to our ArtemisAI software platform.

The human body is a holistic system, its biology is multi-faceted and intricately interconnected. Traditional drug discovery and development efforts have relied on simplified models and reductionistic tools to discover and test new drugs. Now it's time to make a change. Xellar is a Wet-AI, Artificial Intelligence and machine learning combined with large-scale wet-lab experiments, biotech company tackling the most challenging problem in modern drug discovery – harnessing the complexity of human biology to accelerate drug discovery and development.

We are a quantum physics-based, AI-powered drug R&D company with the mission to revolutionize drug discovery and development by improving the speed, scale, novelty and success rate. With operations in both China and the U.S., we strive to deploy the best capabilities and resources available to us in each market to meet the needs of our customers and collaborators. Beyond our team’s domain expertise and creative thinking, the key to our mission is the integrated technology platform, which combines the mutually informing and reinforcing cloud supercomputing-powered in silico tools and our wet lab with robotic automation, and enables discovery and development of innovative therapeutics at a pace and scale beyond traditional alternatives. We are among the pioneering AI-powered drug R&D companies in the world that have established a platform with an iterative feedback loop between quantum physics-based dry lab and wet lab capabilities, according to Frost & Sullivan. With our platform designed to improve dry lab calculations with experimental data generated by the wet lab and enhance the efficiency of the wet lab by insights derived from dry lab calculations, we believe that we are well positioned at this moment where the combination of AI, computing power, data and automation is becoming increasingly critical for pharmaceutical development. Since our founding, we have received investments and support from world-renowned investors, and we believe this blue-chip shareholder base is a testament to our capabilities and prospects.

Yurogen Biosystems LLC is a private biotech company based in the Greater Boston area, a world-class biotech and biopharma hub. We are dedicated to produce premium antibodies and antibody-based products to meet broad needs of our clients. Along with our traditional polyclonal antibody production, Yurogen is commercializing an innovative platform that can efficiently develop monoclonal antibodies from a variety of host animals especially rabbit. Yurogen is developing a selection of antibodies that are widely used in in vitro diagnostics (IVD) as well as academic research. Our growing list of high quality antibodies are the reliable and cost-efficient tools that you can count on. Customized antibody services is offered at Yurogen to generate antibodies to meet the needs of our clients. Our state-of-the-art monoclonal antibody screening platform can significantly shorten the antibody screening process and yield high affinity monoclonal antibodies.

Zeta Surgical is a digital surgery company based in Boston, Massachusetts, founded in 2018. The company specializes in enhancing the accuracy, safety, and accessibility of image-guided procedures through advanced navigation and robotics. Their flagship product, the RealTrack computer vision system, offers sub-millimeter precision and automatic registration, streamlining surgical workflows and improving efficiency in operating rooms. Zeta Surgical collaborates with leading hospitals and universities, including Massachusetts General Hospital and Brigham and Women’s Hospital, to integrate its technology into top medical institutions. The company has received multiple awards for its innovative designs, including the 2023 iF Design Award and the Integra Award for Innovation. Zeta Surgical's products are FDA 510(k) cleared and the company is ISO 13485:2016 certified, ensuring high standards in medical device quality management.